This phase II trial compares the safety and effect of temozolomide combined with survivin long peptide vaccine (SurVaxM) to temozolomide alone in patients with neuroendocrine tumors (NET) that has spread from where it first started (primary site) to other places in the body (metastatic) and is growing, spreading or getting worse (progressing). Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill tumor cells and slow down or stop tumor growth. Survivin, a protein, is expressed in 50% of patients that have neuroendocrine tumors and, is associated with poor outcomes. SVN53-67/M57-KLH peptide vaccine (SurVaxM) is a vaccine that has been shown to produce an immune system response against cancer cells that express a survivin and may block the growth of new tumor cells. Giving temozolomide with SurVaxM may kill more tumor cells in patients with progressing metastatic neuroendocrine tumors.

开始日期2024-07-15

申办/合作机构

Roswell Park Comprehensive Cancer Center

NCT04978727 / Recruiting临床1期IIT

A Pilot Study of Safety, Tolerability, and Immunological Effects of SurVaxM in Pediatric Patients With Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Patients will receive a vaccine called SurVaxM on this study. While vaccines are usually thought of as ways to prevent diseases, vaccines can also be used to treat cancer. SurVaxM is designed to tell the body's immune system to look for tumor cells that express a protein called survivin and destroy them. The survivin protein can be found on up to 95% of glioblastomas and other types of cancer but is not found in normal cells. If the body's immune system knows to destroy cells that express survivin, it may help to control tumor growth and recurrence.
SurVaxM will be mixed with Montanide ISA 51 before it is given. Montanide ISA 51 is an ingredient that helps create a stronger immune response in people, which helps the vaccine work better.
This study has two phases: Priming and Maintenance. During the Priming Phase, patients will get one dose of SurVaxM combined with Montanide ISA 51 through a subcutaneous injection (a shot under the skin) at the start of the study and every 2 weeks for 6 weeks (for a total of 4 doses). At the same time that patients get the SurVaxM/Montanide ISA 51 injection, they will also get a second subcutaneous injection of a medicine called sargramostim. Sargramostim is given close to the SurVaxM//Montanide ISA 51 injection and works to stimulate the immune system to help the SurVaxM/Montanide ISA 51 work more effectively.
If a patient completes the Priming Phase without severe side effects and his or her disease stays the same or improves, he or she can continue to the Maintenance Phase. During the Maintenance Phase, the patient will get a SurVaxM/Montanide ISA 51 dose along with a sargramostim dose about every 8 weeks for up to two years.
After a patient finishes the study treatment, the doctor and study team will continue to follow his/her condition and watch for side effects up to 3 years following the last dose of SurVaxM/Montanide ISA 51. Patients will be seen in clinic every 3 months during the follow-up period.

开始日期2022-07-01

申办/合作机构

National Cancer Institute

[+1]

NCT05163080 / Active, not recruiting临床2期

Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)

The main purpose of this study is to determine whether adding SurVaxM to standard-of-care temozolomide chemotherapy is better than temozolomide treatment alone for patients with newly diagnosed glioblastoma. This study is designed to compare the length of survival in patients with newly diagnosed glioblastoma who receive temozolomide plus SurVaxM to that of patients treated with standard-of-care temozolomide plus placebo. This study aims to discover what effects, both good and bad, this combination of drugs may have on you and to see if the study drug (SurVaxM) can create an immune response in your blood that is directed against your cancer cells. This study also aims to determine whether treatment with SurVaxM plus temozolomide improves the survival of glioblastoma patients like yourself compared to treatment with temozolomide alone.

开始日期2021-11-18

申办/合作机构

Mimivax LLC

[+2]

100 项与 SurVaxM 相关的临床结果

登录后查看更多信息

100 项与 SurVaxM 相关的转化医学

登录后查看更多信息

100 项与 SurVaxM 相关的专利（医药）

登录后查看更多信息

项与 SurVaxM 相关的文献（医药）

2023-12-01·Life sciences

Targeting survivin for cancer therapy: Strategies, small molecule inhibitors and vaccine based therapeutics in development

Review

作者: Coumar, Mohane Selvaraj ; Arya, Hemant ; Ramachandran, Hema Kasthuri ; Kondapuram, Sree Karani

Survivin is a member of the family of inhibitors of apoptosis proteins (IAPs). It is involved in the normal mitotic process and acts as an anti-apoptotic molecule. While terminally differentiated normal tissues lack survivin, several human malignancies have significant protein levels. Resistance to chemotherapy and radiation in tumor cells is associated with survivin expression. Decreased tumor development, apoptosis, and increased sensitivity to chemotherapy and radiation are all effects of downregulating survivin expression or activity. As a prospective cancer treatment, small molecules targeting the transcription and translation of survivin and molecules that can directly bind with the survivin are being explored both in pre-clinical and clinics. Pre-clinical investigations have found and demonstrated the effectiveness of several small-molecule survivin inhibitors. Unfortunately, these inhibitors have also been shown to have off-target effects, which could limit their clinical utility. In addition to small molecules, several survivin peptide vaccines are currently under development. These vaccines are designed to elicit a cytotoxic T-cell response against survivin, which could lead to the destruction of tumor cells expressing survivin. Some survivin-based vaccines are advancing through Phase II clinical studies. Overall, survivin is a promising cancer drug target. However, challenges still need to be addressed before the survivin targeted therapies can be widely used in the clinics.

2023-03-13·Vaccines

Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study.

Article

作者: Rubsamen, Reid M ; Harris, Paul E ; Carback, Richard T ; Herst, Charles V ; Burkholz, Scott R

A triple negative breast cancer model using the murine 4T1 tumor cell line was used to explore the efficacy of an adjuvanted survivin peptide microparticle vaccine using tumor growth as the outcome metric. We first performed tumor cell dose titration studies to determine a tumor cell dose that resulted in sufficient tumor takes but allowed multiple serial measurements of tumor volumes, yet with minimal morbidity/mortality within the study period. Later, in a second cohort of mice, the survivin peptide microparticle vaccine was administered via intraperitoneal injection at the study start with a second dose given 14 days later. An orthotopic injection of 4T1 cells into the mammary tissue was performed on the same day as the administration of the second vaccine dose. The mice were followed for up to 41 days with subcutaneous measurements of tumor volume made every 3-4 days. Vaccination with survivin peptides was associated with a peptide antigen-specific gamma interferon enzyme-linked immunosorbent spot response in the murine splenocyte population but was absent from the control microparticle group. At the end of the study, we found that vaccination with adjuvanted survivin peptide microparticles resulted in statistically significant slower primary tumor growth rates in BALB/c mice challenged with 4T1 cells relative to the control peptideless vaccination group. These studies suggest that T cell immunotherapy specifically targeting survivin might be an applicable neoadjuvant immunotherapy therapy for triple negative breast cancer. More preclinical studies and clinical trials are needed to explore this concept further.

2023-03-01·Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Article

作者: Curry, William T. ; Birkemeier, Meaghan T. ; Dharma, Sanam S. ; Dhawan, Andrew ; Ciesielski, Michael J. ; Ahluwalia, Manmeet S. ; Abad, Ajay P. ; Peereboom, David M. ; Mechtler, Laszlo L. ; Mogensen, Kathleen M. ; Qiu, Jingxin ; Belal, Ahmed N. ; Casucci, Danielle M. ; Fenstermaker, Robert A. ; Hutson, Alan D. ; Withers, Henry G. ; Liu, Song ; Wong, Eric T. ; Reardon, David A. ; Figel, Sheila A.

PURPOSE:

Despite intensive treatment with surgery, radiation therapy, temozolomide (TMZ) chemotherapy, and tumor-treating fields, mortality of newly diagnosed glioblastoma (nGBM) remains very high. SurVaxM is a peptide vaccine conjugate that has been shown to activate the immune system against its target molecule survivin, which is highly expressed by glioblastoma cells. We conducted a phase IIa, open-label, multicenter trial evaluating the safety, immunologic effects, and survival of patients with nGBM receiving SurVaxM plus adjuvant TMZ following surgery and chemoradiation (ClinicalTrials.gov identifier: NCT02455557 ).

METHODS:

Sixty-four patients with resected nGBM were enrolled including 38 men and 26 women, in the age range of 20-82 years. Following craniotomy and fractionated radiation therapy with concurrent TMZ, patients received four doses of SurVaxM (500 μg once every 2 weeks) in Montanide ISA-51 plus sargramostim (granulocyte macrophage colony-stimulating factor) subcutaneously. Patients subsequently received adjuvant TMZ and maintenance SurVaxM concurrently until progression. Progression-free survival (PFS) and overall survival (OS) were reported. Immunologic responses to SurVaxM were assessed.

RESULTS:

SurVaxM plus TMZ was well tolerated with no serious adverse events attributable to SurVaxM. Of the 63 patients who were evaluable for outcome, 60 (95.2%) remained progression-free 6 months after diagnosis (prespecified primary end point). Median PFS was 11.4 months and median OS was 25.9 months measured from first dose of SurVaxM. SurVaxM produced survivin-specific CD8+ T cells and antibody/immunoglobulin G titers. Apparent clinical benefit of SurVaxM was observed in both methylated and unmethylated patients.

CONCLUSION:

SurVaxM appeared to be safe and well tolerated. The combination represents a promising therapy for nGBM. For patients with nGBM treated in this manner, PFS may be an acceptable surrogate for OS. A large randomized clinical trial of SurVaxM for nGBM is in progress.

项与 SurVaxM 相关的新闻（医药）

2024-05-30

·PRNewswire

US FDA awards Supplemental Orphan Drug Designation to SurVaxM to now include treatment of Malignant Glioma

The U.S. Food and Drug Administration (FDA) has granted supplemental orphan-drug designation (ODD) to SurVaxM for use in patients with malignant gliomas. New orphan designation broadens the patient population for potential use of SurVaxM to include forms of adult and pediatric malignant gliomas other than glioblastoma. ODD expands market exclusivity of SurVaxM beyond its previous designation of adult glioblastoma. BUFFALO, N.Y., May 30, 2024 /PRNewswire/ -- MimiVax Inc, a clinical-stage biotechnology company developing immunotherapeutics for cancer and autoimmune diseases, today announced that the United States Food and Drug Administration (FDA) has awarded a supplemental orphan drug designation to MimiVax's SurVaxM vaccine to now include malignant glioma. Currently, SurVaxM vaccine is being studied as a treatment for newly diagnosed glioblastoma (nGBM) in a phase 2b randomized clinical study (the SURVIVE trial) which will assess the efficacy of SurVaxM in a large patient population with nGBM. This supplemental orphan drug designation greatly expands the potential for SurVaxM's use in other forms of pediatric and adult malignant gliomas. An orphan drug designation plays a critical role in encouraging the development of treatments for rare diseases, ultimately improving the lives of patients who might otherwise have few or no treatment options. (PRNewsfoto/MimiVax, LLC)

孤儿药临床2期免疫疗法疫苗

2024-01-09

·PRNewswire

MimiVax Announces New Investments to Support Clinical Development of SurVaxM in Glioblastoma

Investors feature leading brain tumor venture philanthropy funds including the Brain Tumor Investment Fund (BTIF) and The Sontag Innovation The along with MEDA Angels, Varia Ventures and private investors. Investment catalyzed by positive results from Phase 2a study of SurVaxM in newly diagnosed glioblastoma (ndGBM) published in the Journal of Clinical Oncology. Funding will support the ongoing Phase 2b clinical study and subsequent registration-related initiatives. BUFFALO, N.Y., Jan. 9, 2024 /PRNewswire/ -- MimiVax, Inc., a biotechnology company focused on the development of SurVaxM, a survivin-targeted vaccine therapy for glioblastoma and other cancers, today announced new investments from the venture philanthropy arms of leading brain tumor patient organizations, VC, private and existing investors. Continue Reading MimiVax Announces New Investments to Support Clinical Development of SurVaxM in Glioblastoma Post this (PRNewsfoto/MimiVax, LLC) The investments from the Brain Tumor Investment Fund (BTIF), an affiliate of the National Brain Tumor Society (NBTS), the Sontag Innovation Fund, LLC, a subsidiary of the Sontag Foundation, the MEDA Angels, LLC, Varia Ventures and private investors will support the ongoing phase 2b clinical study, subsequent registration-related work and prepare the company for commercialization of SurVaxM for ndGBM. Glioblastoma is a rare but deadly cancer with median overall survival of only about 16 months. SurVaxM was developed to bring a paradigm shift to a field that has seen little advancement in decades. MimiVax is rapidly enrolling subjects in its SURVIVE trial [NCT05163080], a randomized, blinded, placebo-controlled Phase 2b clinical trial of SurVaxM among patients with ndGBM at 11 cancer centers across the USA. This follows the successful Phase 2a study published in the Journal of Clinical Oncology having met its primary endpoint, achieving a median overall survival (mOS) of 25.9 months – and further reporting that 41% of the patients receiving SurVaxM survived at least 3 years, with several long term progression-free survivors. Investment funding is designed to help MimiVax achieve its goal of revolutionizing the landscape of brain tumor treatment. "We are honored to receive significant investments from The Brain Tumor Investment Fund, The Sontag Innovation Fund, MEDA Angels, Varia Ventures along with our private investors. "Their confidence in our mission further propels our efforts to make a meaningful impact in the lives of those affected by brain tumors," said Michael Ciesielski, CEO, MimiVax, Inc. The Brain Tumor Investment Fund, known for its dedication to funding pioneering solutions in neuro-oncology, expressed enthusiasm about the partnership. "Brain tumor patients and caregivers desperately need better outcomes. The results seen in previous trials of SurVaxM make us optimistic for the SURVIVE Phase 2b trial and the potential for a new treatment on the horizon" said John Higgins, Managing Director of BTIF. The MEDA Angels, (part of the Tech Coast Angels (TCA) network) are a health-care focused investor group founded by physician, payers and scientist-angel investors, supported by a team of regulatory, reimbursement, legal and financial advisors. "We knew the grave unmet need for game-changing therapy for glioblastoma, a devasting brain cancer with so limited average survival time of 16 months. After review of MimiVax' approach, targeting a strong epitope and the data through their Phase 2a, we became confident they were well worth backing." -MEDA Angels The Sontag Innovation Fund, building on the reputation of the Sontag Foundation as one of the largest private funders of brain tumor research in North America, is proud to have MimiVax as a portfolio company. "There is an extraordinary unmet need for new treatments that make a major impact in the brain tumor space. We are excited to play a role in the development of promising therapies like SurVaxM" said Scott Davis, Managing Director of the Sontag Innovation Fund. MimiVax extends its gratitude to The Brain Tumor Investment Fund, The Sontag Innovation Fund, MEDA Angels, Varia Ventures and our private investors for their support and confidence in the company's vision. This investment fortifies MimiVax's position as a key player in the quest for innovative solutions in the fight against brain tumors. About MimiVax, Inc MimiVax, Inc. is a Delaware-incorporated, clinical-stage biotechnology company focused on immunotherapy research and clinical translation of new agents for cancer treatment. The Company was formed to develop and commercialize its lead candidate SurVaxM. For more information on MimiVax, visit or email [email protected]. About SurVaxM SurVaxM is a first-in-class, patented immunotherapy that targets survivin, a cell-survival protein. SurVaxM is delivered subcutaneously and stimulates a patients' own immune response to control tumor growth and prevent future disease recurrence. Because survivin is present in many forms of cancer, SurVaxM could potentially have wide therapeutic applicability. About the Brain Tumor Investment Fund The Brain Tumor Investment Fund (BTIF) is the non-profit venture philanthropy arm of the National Brain Tumor Society (NBTS), the largest patient advocacy organization in the United States committed to curing brain tumors and improving the lives of patients and families. BTIF BTIF) invests in innovative biotechnology, pharmaceutical, and medical device companies developing promising new treatment opportunities for patients with brain cancer. () About The Sontag Innovation Fund The Sontag Innovation Fund, a wholly-owned venture subsidiary of The Sontag Foundation, one of the largest private funders of brain cancer research in the United States, made the investment. The Sontag Innovation Fund invests in early stage and innovative technologies with the potential to drive cures and improve the quality of life or life expectancy for brain cancer patients. () About MEDA Angels The MEDA Angels are a healthcare-focused angel investor group that invests liberally across mid-seed and Series A healthcare opportunities: both disease management and prevention. Importantly, many startups see an investment by MEDA as validation of the merits of their technology, as potential users, and payer friendly products. () About Varia Ventures Varia Ventures is a next generation venture capital platform for professional organizations interested in building wealth for themselves and their members through investing in a portfolio of highly curated, emerging companies, originating from their organizations. Varia's platform blends insights from key opinion leaders, strategic partners, and industry experts through its "end-to-end" technology solution designed to support early stage companies while providing compelling investment opportunities to its investors. () SOURCE MimiVax, Inc.

临床2期免疫疗法疫苗

2023-12-13

·今日头条

生存期翻2倍，延缓恶性脑肿瘤复发！FDA授予癌症疫苗快速通道认定

2020年秋天，61岁的W先生被确诊为最致命的脑肿瘤--胶质母细胞瘤，生命进入倒计时，因为这类癌症的平均生存时间仅为 12 至 18 个月...幸运的是，他找到了一种可以延缓复发的癌症疫苗--SurVaxM。令他万万没想到的是，接受治疗后他的脑瘤至今未复发，目前3年过去了，他仍在旅行并享受生活。近期，美国FDA传来喜讯，授予“胶质瘤治疗性疫苗SurVaxM”快速通道认定，用于治疗四级胶质母细胞瘤患者。SurVaxM疫苗正在克利夫兰和罗斯维尔公园癌症研究所进行临床试验，结果显示：在 63 名患者参与的试验中显示，其生存时间几乎延长了一倍。有望给处于绝境的胶质瘤患者带来救赎。延缓复发！新型疫苗让晚期患者恶性脑肿瘤患者重回正常生活 2020年秋天，家住纽约州的61岁大叔 J先生被诊断出患有胶质母细胞瘤。据美国国家脑肿瘤协会发言人汤姆哈尔金称，去年美国有超过 14,000 人被确诊。它几乎占所有恶性脑肿瘤的一半。这种疾病对患者和家庭来说是毁灭性的，五年生存率仅为 6.8% 。更糟的是，胶质母细胞瘤极难治疗，因为它们会像蜘蛛网或章鱼触手的形式在大脑内蔓延，即使手术，也无法完全清除，除非每个癌细胞都被消灭，否则 100% 的患者会面临复发！幸运的是，J先生的女儿在美国罗斯威尔公园综合癌症中心工作，当时这家权威的癌症中心正在进行一项专门针对这类恶性脑瘤的新型癌症疫苗的临床实验。医生说，这种名为 SurVaxM 的疫苗以一种在肿瘤中发现的名为Survivin的细胞存活蛋白质为目标，当疫苗注射入体内时，能够刺激免疫系统杀死含有 survivin 的肿瘤细胞。此外，SurVaxM疫苗可以训练免疫系统瞄准并攻击癌细胞，因此当癌细胞复发时，身体可以迅速将它们清除掉，控制肿瘤生长和预防或延缓肿瘤复发。这听起来像是一个遥不可及的幻想：一种可以延迟胶质母细胞瘤复发的疫苗？胶质母细胞瘤可是最致命和治疗耐药的癌症之一！实际上，在一项早期临床试验中，SurVaxM 疫苗被证实可以将被诊断患有脑癌的人的平均生存时间从大约12个月延长至 26 个月，这是非常了不起的突破！经过多番申请，J先生幸运的通过“同情用药”计划接受了这款前沿的癌症疫苗的治疗。这种疫苗就像流感疫苗或新冠疫苗一样注射在手臂上，由四剂组成，分期两个月，然后每两个月注射一剂加强剂量。两年半后，J先生仍在旅行并享受生活——这对于平均存活时间仅为1年的恶性脑瘤患者来说是非常罕见的。（注：为保护患者隐私，文中均使用化名，病情及治疗经过略有删减，想查看原文献的可以点击文末链接。）延缓恶性脑肿瘤复发！FDA授予SurvaxM快速通道认定看了上面的报道，相信很多人想知道这款疫苗究竟是何方神圣？ SurVaxM，也称为SVN53-67 / M57-KLH，是一款全球首创的肽模拟肿瘤疫苗，可以靶向一种叫做 Survivin的细胞存活蛋白。Survivin是一种抗凋亡蛋白，可帮助癌细胞抵抗常规治疗，在许多癌症（包括95%的恶性神经胶质瘤，多发性骨髓瘤，神经内分泌，髓母细胞瘤，黑素瘤，肾脏，乳腺和卵巢肿瘤）中都高度表达。 SurVaxM疫苗具有独特的细胞和抗体介导的抗肿瘤反应，能够同时触发T细胞和B细胞免疫以及抗体导向survivin通路抑制的双重作用机制，刺激免疫系统杀死含有survivin的肿瘤细胞，控制肿瘤生长和预防或延缓肿瘤复发。由于这是一种合成疫苗，是由天然氨基酸制成的，并且在产生免疫反应时会分解，因此副作用很小。 2017年SurVaxM被美国食品和药物管理局（FDA）授予了孤儿药称号。 2023年10月，FDA再次授予这款疫苗快速通道制定。 2023年3月，SurVaxM的Ⅱa期临床试验数据发表在国际知名肿瘤期刊《临床肿瘤学杂志》上。最新结果表明，免疫疗法SurVaxM疫苗即使在最难治疗的患者亚组中也具有安全性，良好的耐受性，并且能够延长生存期延长的生存期。引起巨大轰动。 63例新诊断为胶质母细胞瘤的患者进行了标准护理加SurVaxM的治疗。研究表明：该治疗组合耐受良好。观察到的副作用通常是轻度的，在这项研究中看到的唯一副作用是注射部位周围的皮肤反应或皮疹； 96.7％的患者在开始这种治疗组合后的头六个月内未经历疾病进展； 94.2％的研究参与者在诊断后一年还活着，这大大超过了仅标准护理的历史研究（65％）；接受SurVaxM的患者的中位总体生存时间为30.5个月，而接受标准护理的患者为14.8个月。翻了一倍多。目前SurVaxM 疫苗的临床实验计划招募 270 名患者。预计将在美国和中国的 10 多个地点进行，将注射疫苗与接受标准护理的患者进行比较。一旦开始招募，这将是全球脑瘤患者的福音。期待这款疫苗能够早日获批上市。溶瘤病毒、树突疫苗、电场疗法等众多疗法为脑瘤患者打开长生存大门在过去15年中，400多个胶质母细胞瘤临床试验都失败了....终于，针对这一毁灭性癌症，近两年众多新疗法横空出世，除了上文值得期待的脑瘤疫苗，溶瘤病毒、树突疫苗、电场疗法等也为脑瘤患者带来了全新的生机。一：全球首款脑瘤溶瘤病毒获批上市！ 2021年6月11日，世界上首款治疗原发性脑瘤的溶瘤病毒疗法teserpaturev在日本获批的喜讯在癌友圈中刷屏，给病友们带来了新的生存希望，2021年11月1日，溶瘤病毒疗法正式在日本获批用于临床治疗。二：15年磨一剑！脑瘤疫苗横空出世研究人员花费了将近20年的时间致力于激活抗脑癌的树突状细胞。近期，令全球备受瞩目的脑瘤树突细胞疫苗DCVax®-L研究终于公布了III期临床实验的顶线数据，结果显示，DCVax®-L疫苗能够显著延长脑胶质瘤患者的生存期，最值得一提的是，5 年生存率统计显示：疫苗组为13%，而对照组仅为5.7%，翻了一倍多！至此，这项长达15年的研究终于交出了满意的答卷，也给无数饱受摧残的脑瘤患者带来了全新的希望！三：5年无复发！无创抗癌新技术成功治疗恶性脑瘤电场疗法被称为是脑瘤治疗的里程碑！这是十多年来第一次，出现了一种非有效地疗法，能够显著的提高脑质母细胞瘤患者的生存期！已经有研究表明，手术、化疗和放疗来治疗脑胶质瘤，5年的生存几率为 5%。如果75% 的时间佩戴 Optune，存活几率会增加到 13%。如果有 90% 到 100% 的时间穿着它，5年生存率会增加到 29%，几乎可以延长6倍！给脑瘤患者带来了史无前例的生存突破除了上面的这些疗法，对于脑瘤患者，现在医学界更提倡通过多种治疗手段进行综合治疗，包括局部放化疗、靶向和免疫等，需要针对患者的具体情况综合考虑，量身定制。因此，在如何选择最佳治疗方案和用药上可以通过全球肿瘤医生网求助于国内外权威专家，这样才能让广大癌友们少走弯路，得到最大的临床获益。想寻求电场疗法及其他国内外治疗新技术帮助，且经济条件允许的情况下，可以提交资料全球肿瘤医生网医学部进行初步评估。脑瘤并不可怕，希望大家坚定信心，通过规范合理的治疗，获得更长的生存期！参考资料： https://www.nbcnews.com/health/health-news/brain-tumor-vaccine-experimental-shot-shows-promise-glioblastoma-rcna83362 DOI: 10.1200/JCO.22.00996 Journal of Clinical Oncology 41, no. 7 (March 01, 2023) 1453-1465.

疫苗快速通道临床研究临床结果信使RNA

100 项与 SurVaxM 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胃肠胰神经内分泌肿瘤	临床2期	美国	Roswell Park Comprehensive Cancer Center	2024-07-15
恶性实体肿瘤	临床2期	美国	Roswell Park Comprehensive Cancer Center	2024-07-15
肺神经内分泌肿瘤	临床2期	美国	Roswell Park Comprehensive Cancer Center	2024-07-15
胰腺神经内分泌肿瘤	临床2期	美国	Roswell Park Comprehensive Cancer Center	2024-07-15
胶质母细胞瘤	临床2期	美国	Roswell Park Comprehensive Cancer Center	2015-05-04
神经胶质肉瘤	临床2期	美国	Roswell Park Comprehensive Cancer Center	2015-05-04
类癌	临床1期	美国	Roswell Park Comprehensive Cancer Center	2019-06-17
胰腺神经内分泌肿瘤转移	临床1期	美国	Roswell Park Comprehensive Cancer Center	2019-06-17
浆细胞白血病	临床1期	美国	Celgene Corp.	2017-04-13
浆细胞白血病	临床1期	美国	Roswell Park Comprehensive Cancer Center	2017-04-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02455557 (Pubmed)	临床2期	胶质母细胞瘤辅助	66	SurVaxM plus adjuvant TMZ	夢顧壓築廠鏇網觸繭糧(齋窪觸鬱糧糧餘艱築鹹) = 鹹窪構積鹽獵夢積鬱願顧廠夢積衊積艱壓窪鹽 (壓艱鹽簾夢鏇醖鹹選鬱 ) 更多	积极	2022-12-15
NCT02455557 (ASCO2022)	临床2期	胶质母细胞瘤	63	SurVaxM	鬱繭壓艱觸鑰憲艱鹹網(顧繭壓遞築觸獵構衊顧) = 膚遞襯齋願襯鹽構夢糧選簾獵膚製積構憲壓遞 (膚鑰觸餘獵憲糧夢夢衊 )	积极	2022-06-02
NCT02455557 (CTgov)	临床2期	神经胶质肉瘤 \| 胶质母细胞瘤	66	Laboratory Biomarker Analysis+Temozolomide+Montanide ISA 51 VG+Sargramostim+SVN53-67/M57-KLH Peptide Vaccine	築顧鏇齋蓋憲醖餘醖糧(顧糧繭齋獵糧構齋構餘) = 淵繭窪獵窪簾醖齋繭網鑰衊積艱醖壓範繭餘願 (築顧鏇獵醖鹹淵製網簾, 膚壓顧製艱齋顧遞壓簾 ~ 餘製觸顧遞鏇膚憲淵鬱) 更多	-	2021-02-01
NCT02455557 (ASCO2019) 人工标引	临床2期	胶质母细胞瘤一线 survivin positive	63	standard therapy+SurVaxM (methylated MGMT)	夢壓壓膚積蓋網糧膚鏇(衊憲鑰構淵糧餘鹹構糧) = injection site reactions 鹹糧範鬱齋鹽窪壓糧襯 (選遞選蓋觸壓顧壓遞鑰 )	积极	2019-05-26
NCT02455557 (ASCO2019) 人工标引	临床2期	胶质母细胞瘤一线 survivin positive	63	standard therapy+SurVaxM (unmethylated MGMT)		积极	2019-05-26
NCT02455557 (ASCO2018)	临床2期	胶质母细胞瘤	63	Standard therapy plus SurVaxM	壓築壓淵獵構鏇齋夢壓(網遞積壓鏇壓夢鏇糧獵) = immunization-related adverse events were mild with no serious adverse events attributable to SurVaxM 艱淵鏇繭鏇夢鬱簾鬱鏇 (製餘鬱憲遞夢糧獵鬱鑰 )	积极	2018-06-01